Cargando…

In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus

Background: The cationic amphiphilic drug U18666A inhibits the proliferation of type I FIPV in vitro. In this study, we evaluated the in vivo antiviral effects of U18666A by administering it to SPF cats challenged with type I FIPV. Methods: Ten SPF cats were randomly assigned to two experimental gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Doki, Tomoyoshi, Tarusawa, Tomoyo, Hohdatsu, Tsutomu, Takano, Tomomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169457/
https://www.ncbi.nlm.nih.gov/pubmed/31963705
http://dx.doi.org/10.3390/pathogens9010067
_version_ 1783523792455204864
author Doki, Tomoyoshi
Tarusawa, Tomoyo
Hohdatsu, Tsutomu
Takano, Tomomi
author_facet Doki, Tomoyoshi
Tarusawa, Tomoyo
Hohdatsu, Tsutomu
Takano, Tomomi
author_sort Doki, Tomoyoshi
collection PubMed
description Background: The cationic amphiphilic drug U18666A inhibits the proliferation of type I FIPV in vitro. In this study, we evaluated the in vivo antiviral effects of U18666A by administering it to SPF cats challenged with type I FIPV. Methods: Ten SPF cats were randomly assigned to two experimental groups. FIPV KU-2 were inoculated intraperitoneally to cats. The control group was administered PBS, and the U18666A-treated group was administered U18666A subcutaneously at 2.5 mg/kg on day 0, and 1.25 mg/kg on days 2 and 4 after viral inoculation. Results: Two of the five control cats administered PBS alone developed FIP. Four of the five cats administered U18666A developed no signs of FIP. One cat that temporarily developed fever, had no other clinical symptoms, and no gross lesion was noted on an autopsy after the end of the experiment. The FIPV gene was detected intermittently in feces and saliva regardless of the development of FIP or administration of U18666A. Conclusions: When U18666A was administered to cats experimentally infected with type I FIPV, the development of FIP might be suppressed compared with the control group. However, the number of animals with FIP is too low to establish anti-viral effect of U18666A in cats.
format Online
Article
Text
id pubmed-7169457
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71694572020-04-22 In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus Doki, Tomoyoshi Tarusawa, Tomoyo Hohdatsu, Tsutomu Takano, Tomomi Pathogens Article Background: The cationic amphiphilic drug U18666A inhibits the proliferation of type I FIPV in vitro. In this study, we evaluated the in vivo antiviral effects of U18666A by administering it to SPF cats challenged with type I FIPV. Methods: Ten SPF cats were randomly assigned to two experimental groups. FIPV KU-2 were inoculated intraperitoneally to cats. The control group was administered PBS, and the U18666A-treated group was administered U18666A subcutaneously at 2.5 mg/kg on day 0, and 1.25 mg/kg on days 2 and 4 after viral inoculation. Results: Two of the five control cats administered PBS alone developed FIP. Four of the five cats administered U18666A developed no signs of FIP. One cat that temporarily developed fever, had no other clinical symptoms, and no gross lesion was noted on an autopsy after the end of the experiment. The FIPV gene was detected intermittently in feces and saliva regardless of the development of FIP or administration of U18666A. Conclusions: When U18666A was administered to cats experimentally infected with type I FIPV, the development of FIP might be suppressed compared with the control group. However, the number of animals with FIP is too low to establish anti-viral effect of U18666A in cats. MDPI 2020-01-18 /pmc/articles/PMC7169457/ /pubmed/31963705 http://dx.doi.org/10.3390/pathogens9010067 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Doki, Tomoyoshi
Tarusawa, Tomoyo
Hohdatsu, Tsutomu
Takano, Tomomi
In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
title In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
title_full In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
title_fullStr In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
title_full_unstemmed In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
title_short In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
title_sort in vivo antiviral effects of u18666a against type i feline infectious peritonitis virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169457/
https://www.ncbi.nlm.nih.gov/pubmed/31963705
http://dx.doi.org/10.3390/pathogens9010067
work_keys_str_mv AT dokitomoyoshi invivoantiviraleffectsofu18666aagainsttypeifelineinfectiousperitonitisvirus
AT tarusawatomoyo invivoantiviraleffectsofu18666aagainsttypeifelineinfectiousperitonitisvirus
AT hohdatsutsutomu invivoantiviraleffectsofu18666aagainsttypeifelineinfectiousperitonitisvirus
AT takanotomomi invivoantiviraleffectsofu18666aagainsttypeifelineinfectiousperitonitisvirus